Details of the Drug Combinations

General Information of This Drug (ID: DMRJLAT)

• Drug Name: Osimertinib (DMRJLAT)
• Synonyms: Tagrisso

Indication

Non-small-cell lung cancer; ICD 11: 2C25.Y; Status: Approved [1]; Melanoma; ICD 11: 2C30; Status: Phase 3 [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Osimertinib + Panobinostat	DCTYAKF	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]

23 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Al3818 + Osimertinib	DCJB3F7	Al3818	Non-Small Cell Lung Cancer With EGFR Mutation	[4]
Aspirin + Osimertinib	DC4ZNYM	Aspirin	Non-Small Cell Lung Cancer Stage IIIB	[5]
Dacomitinib + Osimertinib	DCEN7RW	Dacomitinib	EGFR Gene Mutation	[6]
Gefitinib + Osimertinib	DCXPKLY	Gefitinib	Non-Small Cell Lung Cancer	[7]
INCB039110 + Osimertinib	DCOXCM5	INCB039110	Lung Cancer	[8]
MK-4827 + Osimertinib	DCNCXJ9	MK-4827	Lung Cancer	[9]
MLN8237 + Osimertinib	DC20ZO4	MLN8237	Lung Cancer Metastatic	[10]
Osimertinib + Afatinib	DCW8VJC	Afatinib	Carcinoma, Non-Small-Cell Lung	[11]
Osimertinib + Sapanisertib	DCEGDDP	Sapanisertib	Metastatic Lung Non-Small Cell Carcinoma	[12]
Osimertinib + Dasatinib	DCI069L	Dasatinib	EGFR Gene Mutation	[13]
Triptolide + Osimertinib	DCU2QJA	Triptolide	Advanced Lung Non-Small Cell Carcinoma	[14]
Tucatinib + Osimertinib	DC4LLXV	Tucatinib	Metastatic Lung Non-Small Cell Carcinoma	[15]
Zarnestra + Osimertinib	DCFBG6R	Zarnestra	NSCLC	[16]
Alectinib + Osimertinib	DCTUXIB	Alectinib	Non-Small Cell Lung Cancer	[17]
Dacomitinib + Osimertinib	DCBFNEK	Dacomitinib	NSCLC	[18]
Disulfiram + Osimertinib	DCOHFV6	Disulfiram	Non-Small Cell Lung Cancer	[17]
Gefitinib + Osimertinib	DCVVUG8	Gefitinib	Non-Small Cell Lung Cancer	[17]
LY2835219 + Osimertinib	DC8DL1L	LY2835219	Lung Cancer	[19]
Osimertinib + Tepotinib	DCIXVIX	Tepotinib	Non-small Cell Lung Cancer	[20]
Osimertinib + Capmatinib	DCRDJR2	Capmatinib	Advanced Solid Tumors Which Are cMET-dependent	[21]
Savolitinib + Osimertinib	DCJ7UTK	Savolitinib	Non-Small Cell Lung Cancer	[17]
Selumetinib + Osimertinib	DCGXOY2	Selumetinib	Non-Small Cell Lung Cancer	[17]
Osimertinib + Capmatinib	DC1S8C7	Capmatinib	Carcinoma, Non-Small-Cell Lung	[22]

References

• [1] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7719).
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] ClinicalTrials.gov (NCT04770688) Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
• [5] ClinicalTrials.gov (NCT03543683) Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC
• [6] ClinicalTrials.gov (NCT03755102) A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
• [7] ClinicalTrials.gov (NCT03122717) Osimertinib and Gefitinib in EGFR Inhibitor nave Advanced EGFR Mutant Lung Cancer
• [8] ClinicalTrials.gov (NCT02917993) An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
• [9] ClinicalTrials.gov (NCT03891615) Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
• [10] ClinicalTrials.gov (NCT04085315) Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
• [11] ClinicalTrials.gov (NCT03370770) Afatinib Osimertinib Sequencing NIS
• [12] ClinicalTrials.gov (NCT02503722) Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer
• [13] ClinicalTrials.gov (NCT02954523) Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
• [14] ClinicalTrials.gov (NCT05166616) Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer
• [15] ClinicalTrials.gov (NCT06067776) Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
• [16] ClinicalTrials.gov (NCT05693090) Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
• [17] ClinicalTrials.gov (NCT03944772) Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
• [18] ClinicalTrials.gov (NCT04811001) Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations
• [19] ClinicalTrials.gov (NCT04545710) Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance
• [20] ClinicalTrials.gov (NCT03940703) A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
• [21] ClinicalTrials.gov (NCT03040973) Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
• [22] ClinicalTrials.gov (NCT04816214) Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy